Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.02
Bid: 1.80
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.31 (17.222%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2.02
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Enwell pleased with SV-31; SDX Energy ties in well

Fri, 06th May 2022 19:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Mpac Group PLC - Coventry, England-based packaging company - Says trading in 2022 so far has been in line with expectations. Explains the prospects pipeline is strong and its current order book is "significantly" above the previous year. However, company notes that supply chain uncertainties and operational challenges have increased, amplified by transportation delays. Mitigation measures in place and thus company remains positive. Chief Executive Tony Steels says he expects the full-year to be in line with expectations.

----------

Primorus Investments PLC - London-based investment firm focused on small and mid cap firms in financial services, technology and natural resources - Signs a deed of amendment which extends the time for investee Alteration Earth PLC to complete its prospectus and obtain its listing on the London Stock Exchange. Date has been extended to June 6 from May 4.

----------

Arix Bioscience PLC - London-based venture capital investor in biotech firms - Receives notice Acacia Research Corp that it has increased its ownership of the company. Acacia acquires a further 646,932 shares representing 21% of Arix's share capital. Acacia also notifies Arix that it does not intend to make an offer for the company.

----------

Gunsynd PLC - London-based investment company focused on the natural resources, life sciences and alcohol sector - Gives notice to Sajawin Pty Ltd to terminate the term sheet and variation terms sheet in relation to the disposal of Gunsynd's shareholding in Oyster Oil & Gas Ltd. Gunsynd, in conjunction with other shareholders in Oyster, will now seek alternative avenues to monetise the project.

----------

Pantheon Resources PLC - London-based oil and gas company focused on Alaska - Announces that the holder of its senior unsecured convertible bonds due 2026 has exercised conversion rights for USD3.8 million. Accordingly, the remaining amount under the convertible bonds will be reduced to USD46.6 million.

----------

Open Orphan PLC - London-based pharmaceutical services company - Notes market speculation regarding its potential delisting. Confirm it has no plans to delist and says it is working with Liberum Capital to complete its due diligence.

Separately, company says its subsidiary, hVIVO, has signed a "substantial" contract with an unnamed pharmaceutical client. Contract is manufacture a virus for use in human challenge studies. Adds that virus manufacturing activities have commenced and expected to be completed by the end of the third quarter of 2022. Revenue for the manufacturing process will be recognised in 2022, company says.

----------

Insig AI PLC - London-based data science and machine learning company - Signs agreement for a GBP1.0 million convertible loan note. Note provided by Non-Executive Chair Richard Bernstein. Loan is unsecured and repayable on or before December 31. An initial tranche of GBP250,000 has been drawn down.

----------

Enwell Energy PLC - London-based oil and gas company - Says SV-31 well is currently producing at a stabilised flow rate of 2.7 million standard cubic feet per day of gas and 185 barrels per day of condensate. All operations remain suspended at the Vasyschevskoye gas and condensate field and the Svystunivsko-Chervonolutskyi exploration licence in light of Russian military action in Ukraine. Chief Executive Sergii Glazunov says: "We are very pleased with the results of the SV-31 well, which was drilled safely and successfully, and ahead of schedule. The completion of the well in the current extremely challenging environment in Ukraine is a great achievement by our team, and the strong flow rates recorded will provide a welcome boost to our overall production volumes."

----------

ImmuPharma PLC - London-based drug discovery and development company - Confirms that final preparations are underway to progress Lupuzor into a new phase three trial for lupus patients. Adds that its US partner Avion Pharmaceuticals have confirmed they are requesting final guidance from the US Food & Drug Adminstration to commence the phase three trial. Chief Executive Tim McCathy says: "Following the positive readout from the [pharmacokinetic] study, we have been working closely with the team at Avion to move Lupuzor as quickly as possible to the start of the Phase 3 trial."

----------

SDX Energy PLC - London-based oil and gas company focused on Egypt and Morocco - Completes tie-in of the SD-5X Warda well one month ahead of schedule. The company holds a 37% working interest in the well. Well is now under production test, with first gas achieved on April 27. After the initial flow period, there will be a shut-in of 12 hours followed by a main flow period of five days. Post the main flow period, the well will be shut in for 10 days to monitor the pressure build-up. Chief Executive Mark Reid says: "The well is now contributing to production and cash flow from this asset much earlier than originally anticipated... Once the long-term production profile for the well has been established, we will revise our 2022 production guidance if appropriate."

----------

CleanTech Lithium PLC - Jersey-based lithium exploration and development company focused on Chile - Reports drilling at its Laguna Verde and Francisco Basin. Two drill rigs are now in operation at the Francisco Basin. Upgrades resource estimate for Laguna Verde. Maiden resource estimate for Francisco Basin on track for the second quarter of 2022. Chief Executive Aldo Boitano says: "The resource drilling programmes, which commenced in January 2022 at Laguna Verde and in March 2022 at Francisco Basin, continue to progress well. The Francisco Basin programme has been accelerated with the addition of the second rig, bringing the total number of rigs operating across both sites to three."

----------

Caerus Mineral Resources PLC - Cyprus-based exploration & resource development company focussed on Europe - Returns "consistently anomalous" gold assay results from hand auger drilling and pitting results for the Mala pyrite dump in Cyprus. Reports peak gold grades 9.9 grams per tonne of gold, 1.3 grams per tonne of gold and 1.2 grams per tonne of gold. A total of 55 auger holes and pits return gold grades from 0.1 to 9.9 grams per tonne of gold. Chief Executive Martyn Churchouse says: "The potential gold resource in the pyrite dumps combined with the known sulphide body is an excellent start and provides the confidence we need to commit to further detailed resource development."

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
14 Sep 2022 12:46

IN BRIEF: ImmuPharma receives response for FDA for Lupuzor

ImmuPharma PLC - specialist drug discovery and development company - Says its US partner for Lupuzor, Avion Pharmaceuticals LLC, has received a written response from the US Food & Drug Administration that provided detailed guidance on the next steps for the drug's clinical programme. This included advice on the dosing regime, as well as guidance on the study protocol that can be amended to improve the regulatory outcome.

Read more
7 Sep 2022 09:55

ImmuPharma raises GBP150,000 via issue of 3 million new shares

ImmuPharma PLC - specialist drug discovery and development company - Says L1 Capital Global Opportunities Master Fund has exercised options over 3.0 million new shares at a price of 5 pence each, for GBP150,000 in total. The new shares represent 0.9% of the company's enlarged share capital.

Read more
31 Aug 2022 21:41

TRADING UPDATES: ImmuPharma waits on FDA; IDE Group waits on audit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
11 Aug 2022 19:08

IN BRIEF: ImmuPharma raises GBP950,000 from broker option

ImmuPharma PLC - specialist drug discovery and development company - Raises GBP950,000 under broker option, taking total proceeds from placing and broker option to GBP1.04 million. "Further to the announcement of August 3, 2022, the directors confirm that the fundraising, together with existing funding and funding arrangements, will provide the company with sufficient working capital for at least the next 12 months," it says.

Read more
3 Aug 2022 19:40

IN BRIEF: ImmuPharma to raise funds for investment into pipeline

ImmuPharma PLC - specialist drug discovery and development company - Intends to raise GBP1.1 million through the placing and subscription of 21.8 million shares at a price of 5.0 pence per share.

Read more
7 Jul 2022 20:35

IN BRIEF: ImmuPharma US partner gets Type C meeting with US FDA

ImmuPharma PLC - specialist drug discovery and development company - Says Avion Pharmaceuticals, its US partner for its Lupuzor lupus treatment, received a Type C Meeting confirmation from the US Food & Drug Administration. The London-listed company says statement of purpose, objectives and proposed agenda of the meeting have already been agreed on, as has the option to provide written responses, rather than face-to-face meetings. The FDA has agreed to provide a written response by August 29.

Read more
21 Jun 2022 16:05

UK shareholder meetings calendar - next 7 days

Wednesday 22 June 
ASA International Group PLCAGM
Atalaya Mining PLCAGM
Bonhill Group PLCAGM
Chapel Down Group PLCAGM
Churchill China PLCAGM
Downing Renewables & Infrastructure Trust PLCGM re share issue
Ecofin US Renewables Infrastructure Trust PLCAGM
EJF Investments LtdAGM
Frenkel Topping Group PLCAGM
Good Energy Group PLCAGM
Honeycomb Investment Trust PLCAGM
ICG-Longbow Senior Secured UK Property Debt Investments LtdAGM
Intelligent Ultrasound Group PLCAGM
Iofina PLCAGM
John Wood Group PLCAGM
Kingfisher PLCAGM
LXi REIT PLCGM
Menhaden PLCAGM
North Atlantic Smaller Cos Investment Trust PLCAGM
Pennant International Group PLCAGM
Plant Health Care PLCAGM
Skillcast Group PLCAGM
Team PLCAGM
Tribal Group PLCGM re final dividend
Trident Royalties PLCAGM
Vertu Motors PLCAGM
Wentworth Resources PLCAGM
Thursday 23 June 
Avacta Group PLCAGM
Anglo Asian Mining PLCAGM
Card Factory PLCAGM
Cordiant Digital Infrastructure LtdAGM
Downing Renewables & Infrastructure Trust PLCGM re initial placing & open offer
Eight Capital Partners PLCGM re aligning 2022 bonds with 2026 bonds
GENinCode PLCAGM
Ideagen PLCGM re takeover by Hg Pooled Management Ltd
Longboat Energy PLCAGM
Oxford Nanopore Technologies PLCAGM
Puma VCT 13 PLCGM re cancellation of listing & liquidation
RBG Holdings PLCAGM
Tandem Group PLCAGM
Union Jack Oil PLCAGM
Zinnwald Lithium PLCAGM
Friday 24 June 
AFC Energy PLCGM re fees for non-executive directors
Avast PLCAGM
Devolver Digital IncAGM
Entain PLCAGM
Gulf Keystone Petroleum LtdAGM
Hawkwing PLCAGM
Invesco Bond Income Plus LtdAGM
Life Science REITAGM
Northcoders Group PLCAGM
Princess Private Equity Holding LtdAGM
Monday 27 June 
Anglo-Eastern Plantations PLCAGM
Celadon Pharmaceuticals PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Echo Energy PLCAGM
Medica Group PLCAGM
Pelatro PLCAGM
Surgical Innovations Group PLCAGM
Warpaint London PLCAGM
Tuesday 28 June 
4D Pharma PLCAGM
Acceler8 Ventures PLCAGM
Airtel Africa PLCAGM
Alina Holdings PLCAGM
Aquila Energy Efficiency Trust PLCAGM
Attraqt Group PLCAGM
Bay Capital PLCAGM
Capital & Counties Properties PLCAGM
CMO Group PLCAGM
Corre Energy BVAGM
Creo Medical Group PLCAGM
Futura Medical PLCAGM
Gama Aviation PLCAGM
ICG Enterprise Trust PLCAGM
ImmuPharma PLCAGM
IQE PLCAGM
Katoro Gold PLCAGM
Rockhopper Exploration PLCAGM
Sound Energy PLCAGM
TP Group PLCAGM
UK Oil & Gas PLCAGM
Volvere PLCAGM
Zegona Communications PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
25 May 2022 16:53

IN BRIEF: ImmuPharma shares fall as annual loss widens

ImmuPharma PLC - specialist drug discovery and development company - Widens its pretax loss to GBP8.9 million in 2021 from GBP7.2 million loss the previous year. Loss includes exceptional costs in respect of corporate reorganisation and respective settlement arrangements, company adds. Revenue drops 6.6% to GBP118,350 from GBP126,667. Research and development expenses surge to GBP3.7 million from GBP2.4 million. P140-related expenditure was the main reason for this increase. P140, also known as Llupuzor, is a potential treatment for Lupus. Company does not propose a dividend.

Read more
4 May 2022 13:03

ImmuPharma making final preparations for Lupuzor phase 3 trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma said on Wednesday that final preparations were now underway to progress 'Lupuzor' into its new, optimised international phase 3 trial in lupus patients.

Read more
13 Apr 2022 13:54

ImmuPharma surges on success in latest trial of lupus treatment

(Sharecast News) - Specialist drug discovery and development company ImmuPharma reported positive data from its 'Lupuzor' pharmacokinetic study on Wednesday, as part of the new, optimised international third phase trial in lupus patients.

Read more
13 Apr 2022 12:09

IN BRIEF: Immupharma shares soar on positive data from lupus study

Immupharma PLC - London-based drug discovery and development company - Says its Lupuzor/P140 pharmacokinetic study, required by the US Food & Drug Administration, has met the key endpoints requested. The study is part of an international phase 3 trial of the Lupuzor treatment for patients with lupus disease. The dosing of healthy subjects started on February 15 and showed that P140 was safe and well-tolerated across all doses and in all subjects. Notes that the positive data now clears the path for the start of all clinical studies within the P140 platform. Adds that there is a planned Phase 2a/3 pivotal trial in chronic inflammatory demyelinating polyneuropathy, a rare neurological disorder.

Read more
13 Apr 2022 11:06

AIM WINNERS & LOSERS: ImmuPharma hits milestone; Shearwater contract

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
7 Feb 2022 18:29

TRADING UPDATES: Alphawave teams with Intel; Cadence's Amapa progress

TRADING UPDATES: Alphawave teams with Intel; Cadence's Amapa progress

Read more
7 Feb 2022 13:13

ImmuPharma updates plan for trials of lupus treatment Lupuzor

(Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on the pharmacokinetic study of 'Lupuzor' on Monday, as part of the new, optimised international phase 3 trial of Lupuzor in lupus patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.